Annual report pursuant to Section 13 and 15(d)

Acquisitions, Investments, and Licenses - Textual (Details)

v2.4.1.9
Acquisitions, Investments, and Licenses - Textual (Details)
12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Jun. 30, 2012
SciVac
Variable Interest Entity, Primary Beneficiary
member
Dec. 31, 2014
SciVac
Variable Interest Entity, Primary Beneficiary
USD ($)
Dec. 31, 2014
Cocrystal
Dec. 31, 2014
Sevion
Dec. 31, 2014
ARNO
USD ($)
Dec. 31, 2014
Neovasc
Jan. 31, 2014
Pharmsynthez
Apr. 30, 2013
Pharmsynthez
USD ($)
Apr. 30, 2013
Pharmsynthez
RUB
Dec. 31, 2014
Pharmsynthez
USD ($)
Dec. 31, 2013
Pharmsynthez
USD ($)
Dec. 31, 2014
Zebra
Variable Interest Entity, Not Primary Beneficiary [Member]
Oct. 31, 2013
Zebra
Series A Preferred Stock
Oct. 31, 2013
Zebra
Restricted Stock
Feb. 28, 2013
OPKO Brazil
USD ($)
Dec. 31, 2013
OPKO Brazil
USD ($)
Apr. 17, 2014
Inspiro
USD ($)
Dec. 31, 2014
Inspiro
USD ($)
Apr. 17, 2014
Inspiro
USD ($)
Aug. 31, 2013
OPKO Biologics
USD ($)
Aug. 08, 2014
OPKO Renal
Mar. 31, 2013
OPKO Renal
USD ($)
Aug. 08, 2014
OPKO Renal
USD ($)
Dec. 31, 2013
OPKO Renal
USD ($)
Dec. 31, 2014
ChromaDex [Member]
Dec. 31, 2014
Rxi [Member]
Dec. 31, 2014
NIMS [Member]
Dec. 31, 2014
Cocrystal
Dec. 31, 2014
Pharmsynthez
Dec. 31, 2014
Sevion
Dec. 31, 2014
Neovasc
Dec. 31, 2014
ARNO
Dec. 31, 2014
Other Expense
ARNO
USD ($)
Dec. 31, 2014
Other Income [Member]
USD ($)
Dec. 31, 2013
Other Income [Member]
USD ($)
Dec. 31, 2012
Other Income [Member]
USD ($)
Business Acquisition [Line Items]                                                                              
Inspiro stock purchase agreement                                           100.00%us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
/ us-gaap_BusinessAcquisitionAxis
= opk_InspiroMedicalLtd.Member
                                 
Cash paid at closing date                                   $ 300,000us-gaap_PaymentsToAcquireBusinessesGross
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBrazilMember
  $ 1,500,000us-gaap_PaymentsToAcquireBusinessesGross
/ us-gaap_BusinessAcquisitionAxis
= opk_InspiroMedicalLtd.Member
                                     
Common stock value                                   400,000us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBrazilMember
      8,600,000us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
/ us-gaap_BusinessAcquisitionAxis
= opk_InspiroMedicalLtd.Member
540,600,000us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
/ us-gaap_BusinessAcquisitionAxis
= opk_PROLORMember
  146,900,000us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
21,200,000us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
                         
Number of trading days                                   10 days   10 days         10 days                            
Stock price                                   $ 6.73us-gaap_SharePrice
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBrazilMember
$ 6.73us-gaap_SharePrice
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBrazilMember
  $ 8.57us-gaap_SharePrice
/ us-gaap_BusinessAcquisitionAxis
= opk_InspiroMedicalLtd.Member
$ 8.57us-gaap_SharePrice
/ us-gaap_BusinessAcquisitionAxis
= opk_InspiroMedicalLtd.Member
$ 8.49us-gaap_SharePrice
/ us-gaap_BusinessAcquisitionAxis
= opk_PROLORMember
  $ 7.16us-gaap_SharePrice
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
$ 9.46us-gaap_SharePrice
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
$ 7.16us-gaap_SharePrice
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
                       
In-process research and development 12,055,000us-gaap_ResearchAndDevelopmentInProcess 0us-gaap_ResearchAndDevelopmentInProcess 0us-gaap_ResearchAndDevelopmentInProcess                                 10,100,000us-gaap_ResearchAndDevelopmentInProcess
/ us-gaap_BusinessAcquisitionAxis
= opk_InspiroMedicalLtd.Member
                                     
Shares conversion ratio                                             0.9951opk_BusinessAcquisitionEquityInterestIssuedorIssuableConversionRatio
/ us-gaap_BusinessAcquisitionAxis
= opk_PROLORMember
                               
Delivery of common stock                                   64,684us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBrazilMember
  999,556us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= opk_InspiroMedicalLtd.Member
    63,670,805us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= opk_PROLORMember
2,236,210us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
20,517,030us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
                           
Options and warrants outstanding (shares)                                             7,889,265us-gaap_ClassOfWarrantOrRightOutstanding
/ us-gaap_BusinessAcquisitionAxis
= opk_PROLORMember
                               
Fair value of warrants outstanding                                             46,100,000us-gaap_WarrantsAndRightsOutstanding
/ us-gaap_BusinessAcquisitionAxis
= opk_PROLORMember
                               
Percentage of ownership held by chairman                                             5.00%opk_PercentageofShareholdingbyChairmanofAcquireeCompany
/ us-gaap_BusinessAcquisitionAxis
= opk_PROLORMember
                               
Percentage of ownership held by directors                                             5.00%opk_PercentageofShareholdingbyDirectorsofAcquireeCompany
/ us-gaap_BusinessAcquisitionAxis
= opk_PROLORMember
                               
Business acquisition share price on shares issue                                   $ 4.64opk_BusinessAcquisitionEquityInterestIssuedOrIssuableVolumeWeightedAveragePricePerShare
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKOBrazilMember
  $ 9.00opk_BusinessAcquisitionEquityInterestIssuedOrIssuableVolumeWeightedAveragePricePerShare
/ us-gaap_BusinessAcquisitionAxis
= opk_InspiroMedicalLtd.Member
        $ 4.87opk_BusinessAcquisitionEquityInterestIssuedOrIssuableVolumeWeightedAveragePricePerShare
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
                           
Amount payable in cash or shares on achieving milestones for acquiring a product in development                                                 190,000,000us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
                           
Contingent consideration 71,600,000us-gaap_BusinessCombinationContingentConsiderationLiability 71,600,000us-gaap_BusinessCombinationContingentConsiderationLiability                                             47,700,000us-gaap_BusinessCombinationContingentConsiderationLiability
/ us-gaap_BusinessAcquisitionAxis
= opk_OPKORenalMember
                           
Warrants to purchase common shares           1,000,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_CocrystalMember
100,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_SevionMember
1,700,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ARNOMember
1,000,000us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_NeovascMember
                                                           
Number of shares purchased                     13,600,000opk_EquityMethodInvestmentNumberOfSharesPurchased
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_PharmsynthezMember
13,600,000opk_EquityMethodInvestmentNumberOfSharesPurchased
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_PharmsynthezMember
                                                     
Asset Purchase Agreement                     9,600,000opk_EquityMethodInvestmentAmountOfSharesPurchased
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_PharmsynthezMember
                                                       
Number of share options received in purchase agreement                     12,000,000opk_EquityMethodInvestmentNoteReceivableShareOption
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_PharmsynthezMember
12,000,000opk_EquityMethodInvestmentNoteReceivableShareOption
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_PharmsynthezMember
                                                     
Proceeds to be received from sale of proprietary technology                     8,100,000opk_EquityMethodInvestmentNoteReceivableCashOption
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_PharmsynthezMember
265,000,000opk_EquityMethodInvestmentNoteReceivableCashOption
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_PharmsynthezMember
                                                     
Shares Received In Satisfaction of Notes Receivable                   12,000,000opk_SharesReceivedInSatisfactionofNotesReceivable
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_PharmsynthezMember
                                                         
Deferred revenue 6,700,000us-gaap_DeferredRevenue 8,300,000us-gaap_DeferredRevenue                 9,500,000us-gaap_DeferredRevenue
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_PharmsynthezMember
                                                       
Period for development of technology                     3 years 3 years                                                      
Deferred revenue received from collaboration agreement                         1,400,000opk_DeferredRevenueReceivedFromCollaborationAgreement
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_PharmsynthezMember
8,200,000opk_DeferredRevenueReceivedFromCollaborationAgreement
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_PharmsynthezMember
                                                 
Revenue related to our license agreements                         500,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_PharmsynthezMember
3,800,000us-gaap_LicenseAndServicesRevenue
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_PharmsynthezMember
                                                 
Revenue collaboration agreement, offset to research and development                         1,600,000opk_RevenueReceivedFromCollaborationAgreementOffsettoResearchandDevelopment
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_PharmsynthezMember
1,100,000opk_RevenueReceivedFromCollaborationAgreementOffsettoResearchandDevelopment
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_PharmsynthezMember
                                                 
Investment Owned, Balance, Shares                               840,000us-gaap_InvestmentOwnedBalanceShares
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ZebraMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesAPreferredStockMember
                                             
Cocrystal on a fully diluted basis       50.00%us-gaap_VariableInterestEntityOwnershipPercentage
/ dei_LegalEntityAxis
= opk_SciVacMember
/ us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis
= us-gaap_VariableInterestEntityPrimaryBeneficiaryMember
45.00%us-gaap_VariableInterestEntityOwnershipPercentage
/ dei_LegalEntityAxis
= opk_SciVacMember
/ us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis
= us-gaap_VariableInterestEntityPrimaryBeneficiaryMember
                                                                   
Additional working capital         5,700,000us-gaap_DueFromAffiliates
/ dei_LegalEntityAxis
= opk_SciVacMember
/ us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis
= us-gaap_VariableInterestEntityPrimaryBeneficiaryMember
                                                                   
Number of members of board of directors       5opk_VariableInterestEntityQualitativeorQuantitativeInformationNumberofMembersofBoardofDirectors
/ dei_LegalEntityAxis
= opk_SciVacMember
/ us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis
= us-gaap_VariableInterestEntityPrimaryBeneficiaryMember
                                                                     
Number of members of board of directors appointed by reporting entity       3opk_VariableInterestEntityQualitativeorQuantitativeInformationNumberofMembersofBoardofDirectorsAppointedbyReportingEntity
/ dei_LegalEntityAxis
= opk_SciVacMember
/ us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis
= us-gaap_VariableInterestEntityPrimaryBeneficiaryMember
                                                                     
Percent of board of directors appointed by reporting entity       60.00%opk_VariableInterestEntityQualitativeorQuantitativeInformationPercentofBoardofDirectorsAppointedByReportingEntity
/ dei_LegalEntityAxis
= opk_SciVacMember
/ us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis
= us-gaap_VariableInterestEntityPrimaryBeneficiaryMember
                                                                     
Shares Received As Gift                                 900,000opk_SharesReceivedAsGift
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ZebraMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_RestrictedStockMember
                                           
Investment ownership percentage                             28.00%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ZebraMember
/ us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis
= us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember
23.50%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ZebraMember
/ us-gaap_StatementClassOfStockAxis
= us-gaap_SeriesAPreferredStockMember
                          1.00%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ invest_InvestmentAxis
= opk_NIMSMember
8.00%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ invest_InvestmentAxis
= opk_CocrystalMember
17.00%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ invest_InvestmentAxis
= opk_PharmsynthezMember
4.00%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ invest_InvestmentAxis
= opk_SevionMember
6.00%us-gaap_EquityMethodInvestmentOwnershipPercentage
/ invest_InvestmentAxis
= opk_NeovascMember
         
Total assets of equity method investees 466,700,000us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets                                                                            
Total liabilities of equity method investees 91,500,000us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities                                                                            
Net losses of equity method investees (55,900,000)us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss                                                                            
Equity Method Investment, Quoted Market Value 49,200,000us-gaap_EquityMethodInvestmentQuotedMarketValue                                                                            
Available-for-Sale Securities, Ownership Percentage                                                       2.00%opk_AvailableforSaleSecuritiesOwnershipPercentage
/ invest_InvestmentAxis
= opk_ChromaDexMember
11.00%opk_AvailableforSaleSecuritiesOwnershipPercentage
/ invest_InvestmentAxis
= opk_RxiMember
          4.00%opk_AvailableforSaleSecuritiesOwnershipPercentage
/ invest_InvestmentAxis
= opk_ARNOMember
       
Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net, Available-for-sale Securities                                                                       1,400,000us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_OtherExpenseMember
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ARNOMember
     
Available for sale investments 5,758,000us-gaap_AvailableForSaleSecuritiesNoncurrent             600,000us-gaap_AvailableForSaleSecuritiesNoncurrent
/ us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis
= opk_ARNOMember
                                                             
Gain (Loss) on Sale of Investments $ (167,000)us-gaap_GainLossOnSaleOfInvestments $ 29,881,000us-gaap_GainLossOnSaleOfInvestments $ 0us-gaap_GainLossOnSaleOfInvestments                                                                   $ 1,300,000us-gaap_GainLossOnSaleOfInvestments
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_OtherIncomeMember
$ 29,900,000us-gaap_GainLossOnSaleOfInvestments
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_OtherIncomeMember
$ 0us-gaap_GainLossOnSaleOfInvestments
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_OtherIncomeMember